Paediatric Formulation: Design and Development
The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration;...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2021 |
| Language: | English |
| Physical Description: | 1 electronic resource (205 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04516nam-a2201213z--4500 | ||
|---|---|---|---|
| 001 | 993545879504498 | ||
| 005 | 20231214133045.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202201s2021 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000042816 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/76438 | ||
| 035 | |a (EXLCZ)995400000000042816 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Denora, Nunzio |4 edt | |
| 245 | 1 | 0 | |a Paediatric Formulation: Design and Development |
| 246 | |a Paediatric Formulation | ||
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (205 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration; patient compliance; excipient tolerability. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Globally, about 75% of drugs do not carry regulatory approval for use in children; worldwide, many medications prescribed for the treatment of paediatric diseases are used off-label, and less than 20% of package inserts have sufficient information for treating children. This book provides an update on both state-of-the-art methodology and operational challenges in paediatric formulation design and development. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a dasatinib | ||
| 653 | |a Duchenne muscular dystrophy | ||
| 653 | |a cyclodextrin inclusion complex | ||
| 653 | |a phase solubility studies | ||
| 653 | |a paediatric age | ||
| 653 | |a liquid formulation | ||
| 653 | |a tumorspheres | ||
| 653 | |a retinoblastoma | ||
| 653 | |a topotecan | ||
| 653 | |a penetration | ||
| 653 | |a confocal microscopy | ||
| 653 | |a poorly water soluble drug | ||
| 653 | |a solubility enhancement | ||
| 653 | |a grinding | ||
| 653 | |a spray congealing | ||
| 653 | |a neglected tropical diseases | ||
| 653 | |a polymorph | ||
| 653 | |a Norvir® | ||
| 653 | |a ritonavir | ||
| 653 | |a poorly soluble compound | ||
| 653 | |a pediatric | ||
| 653 | |a palatability assessment | ||
| 653 | |a bioavailability | ||
| 653 | |a flavor profile | ||
| 653 | |a Interleukin-1 | ||
| 653 | |a anakinra | ||
| 653 | |a canakinumab | ||
| 653 | |a innovative biotechnologies | ||
| 653 | |a autoinflammatory disease | ||
| 653 | |a Kawasaki disease | ||
| 653 | |a systemic juvenile idiopathic arthritis | ||
| 653 | |a personalized medicine | ||
| 653 | |a child | ||
| 653 | |a pediatrics | ||
| 653 | |a neonates | ||
| 653 | |a formulation | ||
| 653 | |a product development | ||
| 653 | |a formulation development | ||
| 653 | |a oral | ||
| 653 | |a parenteral | ||
| 653 | |a topical | ||
| 653 | |a inhaled | ||
| 653 | |a intra nasal | ||
| 653 | |a biopharmaceutics | ||
| 653 | |a administration | ||
| 653 | |a excipient | ||
| 653 | |a NICU | ||
| 653 | |a device | ||
| 653 | |a medication error | ||
| 653 | |a dosage form | ||
| 653 | |a modified release | ||
| 653 | |a drug delivery | ||
| 653 | |a paediatric formulation development | ||
| 653 | |a paediatric dosage forms | ||
| 653 | |a chronic myeloid leukemia | ||
| 653 | |a tyrosine kinase inhibitors | ||
| 653 | |a pediatric age | ||
| 653 | |a imatinib | ||
| 653 | |a nilotinb | ||
| 653 | |a ponatinib | ||
| 653 | |a Orodispersible formulation | ||
| 653 | |a pyrazinamide | ||
| 653 | |a pediatric drug delivery | ||
| 653 | |a tuberculosis | ||
| 653 | |a design of experiments | ||
| 653 | |a children | ||
| 653 | |a edible films | ||
| 653 | |a development | ||
| 653 | |a design | ||
| 653 | |a paediatric | ||
| 653 | |a age-related | ||
| 653 | |a palatable | ||
| 653 | |a taste-masking | ||
| 653 | |a acceptable | ||
| 776 | |z 3-0365-0740-X | ||
| 776 | |z 3-0365-0741-8 | ||
| 700 | 1 | |a Lopalco, Antonio |4 edt | |
| 700 | 1 | |a Denora, Nunzio |4 oth | |
| 700 | 1 | |a Lopalco, Antonio |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:41:07 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338076400004498&Force_direct=true |Z 5338076400004498 |b Available |8 5338076400004498 | ||